Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1469-1480

  Strauss, Laura ^a   Bergmann, Christoph ^a,c   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2; OKT 3; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GROWTH INHIBITOR; INTERLEUKIN 2 RECEPTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; ADULT; AGED; BIOSYNTHESIS; BLOOD; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; FEMALE; HEAD AND NECK TUMOR; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GROWTH INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 63149121284     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1469     Document Type: Article

References (51)

1. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761.
2. + T cells secreting IL-10 and TGF-β1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13: 4345-4354.
3. +CD25 T cells via p53, IL-2, and OX40. Proc. Natl. Acad. Sci. USA 104: 15478-15483.
4. Adriani, M., J. Aoki, R. Horai, A. M. Thornton, A. Konno, M. Kirby, S. M. Anderson, R. M. Siegel, F. Candotti, and P. L. Schwartzberg. 2007. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin. Immunol. 124: 41-48.
5. Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, and P. Marrack. 2002. Molecular mechanisms of activated T cell death in vivo. Curr. Opin. Immunol. 14: 354-359.
6. Vence, L., A. K. Palucka, J. W. Fay, T. Ito, Y.-J. Liu, J. Banchereau, and H. Veno. 2007. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 104: 20884-20889.
7. Jiang, S., R. I. Lechler, X. S. He, and J. F. Huang. 2006. Regulatory T cells and transplantation tolerance. Hum. Immunol. 67: 765-776.
8. Sojka, D. K., Y.-H. Huang, and D. J. Fowell. 2008. Mechanisms of regulatory T-cell suppression: a diverse arsenal for a moving target. Immunology 124: 13-22.
9. Arnold, R., D. Brenner, M. Becker, C. R. Frey, and P. H. Krammer. 2006. How T lymphocytes switch between life and death. Eur. J. Immunol. 36: 1654-1658.
10. Roberts, A. I., S. Devadas, X. Zhang, L. Zhang, A. Keegan, K. Greeneltch, J. Solomon, L. Wei, J. Das, E. Sun, et al. 2003. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol. Res. 28: 285-293.
11. Whiteside, T. L. 2006. Lymphocyte homeostasis and the antitumor immune response. Exp. Rev. Clin. Immunol. 1: 369-378.
12. + T cells in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13: 6301-6311.
13. Beyer, M., and J. L. Schultze. 2006. Regulatory T cells in cancer. Blood 108: 804-811.
14. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
15. + regulatory T cells in patients with systemic lupus erythematosus. Adv. Exp. Med. Biol. 601: 113-119.
16. + high T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 150: 75-82.
17. Bour-Jordan, H., B. L. Salomon, H. L. Thompson, G. L. Szot, M. R. Bernhard, and J. A. Bluestone. 2004. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J. Clin. Invest. 114: 979-987.
18. + regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177: 6540-6547.
19. Grossman, W. J., J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson, and T. J. Ley. 2004. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589-601.
20. + T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J. Immunol. 171: 4604-4612.
21. + regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J. Immunol. 175: 32-36.
22. + regulatory T cells cultured with rapamycin. J. Immunol. 178: 320-329.
23. + membraneous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 11: 1010-1020.
24. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193: 1285-1294.
25. + T cells with regulatory properties from human blood. J. Exp. Med. 193: 1303-1310.
26. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193: 1295-1302.
27. + T cell clones in patients with head and neck cancer (HNSCC) and normal controls. Int. J. Cancer. 121: 2473-2483.
28. Strauss, L., C. Bergmann, J. T. Johnson, and T. L. Whiteside. 2006. Expression of Fas ligand (FasL) isoforms on peripheral T-cell subsets in patients with head and neck squamous cell carcinoma (HNSCC). J. Immunother. 29: 670. (Abstr.)
29. + suppressor T cells. Immunol. Rev. 182: 58-67.
30. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17: 221-253.
31. Zhang, X., T. Brunner, L. Carter, R. W. Dutton, P. Rogers, L. Bradley, T. Sato, J. C. Reed, D. Green, and S. L. Swain. 1997. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185: 1837-1849.
32. Hoffmann, T. K., G. Dworacki, T. Tsukihiro, N. Meidenbauer, W. Gooding, J. T. Johnson, and T. L. Whiteside. 2002. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 8: 2553-2562.
33. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
34. Sakaguchi, S., K. Fukuma, K. Kuribayashi, and T. Masuda. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset: I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161: 72-87.
35. Asano, M., M. Toda, N. Sakaguchi, and S. Sakaguchi. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184: 387-396.
36. Chen, X., S. Vodanovic-Jankovic, B. Johnson, M. Keller, R. Komorowski, and W. R. Drobyski. 2007. Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. Blood 110: 3804-3813.
37. + regulatory T cells inhibit protective immunity to filarial parasites in vivo. J. Immunol. 179: 4626-4634.
38. Belkaid, Y., R. B. Blank, and I. Suffia. 2006. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol. Rev. 212: 287-300.
39. + regulatory T cells correlate with chronic hepatitis B infection. Immunology 123: 57-65.
40. Banz, A., C. Pontoux, and M. Papiernik. 2002. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J. Immunol. 169: 750-757.
41. + T regulatory cells: implications and impact on tumor-mediated immune suppression. J. Immunol. 180: 2967-2980.
42. Kemper, C., and J. P. Atkinson. 2007. T-cell regulation: with complements from innate immunity. Nat. Rev. Immunol. 7: 9-18.
43. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174: 1783-1786.
44. Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms, and T. J. Ley. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646.
45. Bergmann, C., L. Strauss, Y. Wang, M. J. Szczepanski, S. Lang, J. T. Johnson, and T. L. Whiteside. 2008. T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 14: 3706-3715.
46. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225-1232.
47. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J.-F. Chen, K. Enjyoji, J. Linden, M. Oukka, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204: 1257-1265.
48. + T cells. Nat. Immunol. 8: 1353-1362.
49. high regulatory cells in human peripheral blood. J. Immunol. 167: 1245-1253.
50. - Tregs, regulate effector T cells using FasL. J. Immunol. 178: 4891-4900.
51. + regulatory T cells. Nat. Med. 11: 1238-1243.